다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Oncotarget, v.8 no.18, 2017년, pp.29760 - 29770
Wen, Yan (Department of Pharmacy, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, P.R. China) , Zhao, Rui-Qiang (Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY 11439, USA) , Zhang, Yun-Kai (Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY 11439, USA) , Gupta, Pranav (Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY 11439, USA) , Fu, Li-Xiang (College of Pharmacy, Guangxi Medical University, Nanning 530021, P.R. China) , Tang, An-Zhou (Department of Otolaryngology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, P.R. China) , Liu, Bu-Ming (Guangxi Key Laboratory of Traditional Chinese Medicine Quality Standards, Guangxi Institute of Chinese Medicine and Pharmaceutical Sciences, Nanning 530022, P.R. China) , Chen, Zhe-Sheng (Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY 11439, USA) , Yang, Dong-Hua (Department) , Liang, Gang
AI-Helper
Cancer cells can acquire resistance to a wide variety of diverse and unrelated drugs, this phenomenon is termed multidrug resistance (MDR). Multidrug resistance has been an obstacle to the success of cancer chemotherapy. The present study investigated the reversal effect of Y6, a new compound obtain...
1 Jemal A Bray F Center MM Ferlay J Ward E Forman D Global cancer statistics CA Cancer J Clin 2011 61 69 90 21296855
2 Rampone B Schiavone B Martino A Viviano C Confuorto G Current management strategy of hepatocellular carcinoma World J Gastroenterol 2009 15 3210 3216 19598295
3 Dong X Mumper RJ Nanomedicinal strategies to treat multidrug-resistant tumors: current progress Nanomedicine (Lond) 2010 5 597 615 20528455
4 Zinzi L Capparelli E Cantore M Contino M Leopoldo M Colabufo NA Small and innovative molecules as new strategy to revert MDR Front Oncol 2015 48 25905037
5 Zhang YK Wang YJ Gupta P Chen ZS Multidrug resistance proteins (MRPs) and cancer therapy AAPS J 2015 17 802 812 25840885
6 Vargas JR Stanzl EG Teng NN Wender PA Cell-penetrating, guanidinium-rich molecular transporters for overcoming efflux-mediated multidrug resistance Mol Pharm 2014 11 2553 2565 24798708
7 Ambudkar SV Kimchi-Sarfaty C Sauna ZE Gottesman MM P-glycoprotein: from genomics to mechanism Oncogene 2003 22 7468 7485 14576852
8 Gottesman MM Fojo T Bates SE Multidrug resistance in cancer: role of ATP–dependent transporters Nat Rev Cancer 2002 2 48 58 11902585
9 Sauna ZE Smith MM Müller M Kerr KM Ambudkar SV The mechanism of action of multidrug-resistance-linked P-glycoprotein J Bioenerg Biomembr 2001 33 481 491 11804190
10 Wang B Peng X Sun R Li J Zhan Xr Lj Wu Wang Sl Xie T Systematic review of β-elemene injection as adjunctive treatment for lung cancer Chin J Integr Med 2012 18 813 823 23086485
11 Wu CP Calcagno AM Ambudkar SV Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies Curr Mol Pharmacol 2008 1 93 105 19079736
12 Thomas H Coley HM Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein Cancer Control 2003 10 159 159 12712010
13 Bissett D Kerr D Cassidy J Meredith P Traugott U Kaye S Phase I and pharmacokinetic study of D-verapamil and doxorubicin Br J Cancer 1991 64 1168 1684909
14 Fischer V Rodríguez-Gascón A Heitz F Tynes R Hauck C Cohen D Vickers AE The Multidrug Resistance Modulator Valspodar (PSC 833) Is Metabolized by Human Cytochrome P450 3A Implications for Drug-Drug Interactions and Pharmacological Activity of the Main Metabolite Drug Metab Dispos 1998 26 802 811 9698296
15 Pusztai L Wagner P Ibrahim N Rivera E Theriault R Booser D Symmans FW Wong F Blumenschein G Fleming DR Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy–resistant, advanced breast carcinoma Cancer 2005 104 682 691 15986399
16 Nobili S Landini I Giglioni B Mini E Pharmacological strategies for overcoming multidrug resistance Current drug targets 2006 7 861 879 16842217
17 Srivastava V Negi AS Kumar J Gupta M Khanuja SP Plant-based anticancer molecules: a chemical and biological profile of some important leads Bioorg Med Chem 2005 13 5892 5908 16129603
18 Kathawala RJ Gupta P Ashby CR Chen ZS The modulation of ABC transporter-mediated multidrug resistance in cancer: A review of the past decade Drug Resist Updat 2015 18 1 17 25554624
19 Liang G Tang A Lin X Li L Zhang S Huang Z Tang H Li QQ Green tea catechins augment the antitumor activity of doxorubicin in an in vivo mouse model for chemoresistant liver cancer Int J Oncol 2010 37 111 20514403
20 Lee MJ Maliakal P Chen L Meng X Bondoc FY Prabhu S Lambert G Mohr S Yang CS Pharmacokinetics of tea catechins after ingestion of green tea and (−)-epigallocatechin-3-gallate by humans formation of different metabolites and individual variability Cancer Epidemiol Biomarkers Prev 2002 11 1025 1032 12376503
21 Liang G Zhang S Huang Z Tang A MDR-reversing effect of two components of catechin on human hepatocellular carcinoma BEL-7404/Adr in vitro [Article in Chinese] Ai zheng 2004 23 401 405 15087027
22 Li JS Effect of N, N-Bis(2-Chloroethyl) docos-13-Enamide on The MDR Reversal of BEL-7404 and Related Mechanism Guangxi Medical University 2016
23 Lambert JD Sang S Hong J Kwon SJ Lee MJ Ho CT Yang CS Peracetylation as a means of enhancing in vitro bioactivity and bioavailability of epigallocatechin-3-gallate Drug Metab Dispos 2006 34 2111 2116 16997910
24 Ou BN The Structural Modification of (−)-Epigallocatechin Gallate and The study of Reversal Activity of Its Derivatives on Multidrugs Resistance of Human Hepatocellular Carcinoma Guangxi Medical University 2011
25 Brown JM Tumor hypoxia in cancer therapy Methods in enzymology 2007 435 295 321
26 Huang L Ao Q Zhang Q Yang X Xing H Li F Chen G Zhou J Wang S Xu G Hypoxia induced paclitaxel resistance in human ovarian cancers via hypoxia-inducible factor 1α J Cancer Res Clin Oncol 2010 136 447 456 19760195
27 Harrison L Blackwell K Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy? Oncologist 2004 9 31 40 15591420
28 Du C Weng X Hu W Lv Z Xiao H Ding C Owusu-anash KG Xie H Zhou L Wu J Hypoxia-inducible MiR-182 promotes angiogenesis by targeting RASA1 in hepatocellular carcinoma J Exp Clin Cancer Res 2015 34 1 25592960
29 Yu G Chen X Chen S Ye W Hou K Liang M Arsenic trioxide reduces chemo-resistance to 5-fluorouracil and cisplatin in HBx-HepG2 cells via complex mechanisms Cancer Cell Int 2015 15 1 25678856
30 Chen MC Hsu WL Hwang PA Chou TC Low molecular weight fucoidan inhibits tumor angiogenesis through downregulation of HIF-1/VEGF signaling under hypoxia Mar Drugs 2015 13 4436 4451 26193287
31 Denko NC Fontana LA Hudson KM Sutphin PD Raychaudhuri S Altman R Giaccia AJ Investigating hypoxic tumor physiology through gene expression patterns Oncogene 2003 22 5907 5914 12947397
32 Prabhakar NR Semenza GL Adaptive and maladaptive cardiorespiratory responses to continuous and intermittent hypoxia mediated by hypoxia-inducible factors 1 and 2 Physiol Rev 2012 92 967 1003 22811423
33 Comerford KM Wallace TJ Karhausen J Louis NA Montalto MC Colgan SP Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene Cancer Res 2002 62 3387 3394 12067980
34 Li J Shi M Cao Y Yuan W Pang T Li B Sun Z Chen L Zhao RC Knockdown of hypoxia-inducible factor-1α in breast carcinoma MCF-7 cells results in reduced tumor growth and increased sensitivity to methotrexate Biochem Biophys Res Commun 2006 342 1341 1351 16516853
35 Song X Liu X Chi W Liu Y Wei L Wang X Yu J Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1α gene Cancer Chemother Pharmacol 2006 58 776 784 16532342
36 Riganti C Doublier S Aldieri E Orecchia S Betta PG Gazzano E Ghigo D Bosia A Asbestos induces doxorubicin resistance in MM98 mesothelioma cells via HIF-1α Eur Respir J 2008 32 443 451 18385176
37 Riganti C Doublier S Viarisio D Miraglia E Pescarmona G Ghigo D Bosia A Artemisinin induces doxorubicin resistance in human colon cancer cells via calcium-dependent activation of HIF-1α and P-glycoprotein overexpression Br J Pharmacol 2009 156 1054 1066 19298255
38 Doublier S Belisario DC Polimeni M Annaratone L Riganti C Allia E Ghigo D Bosia A Sapino A HIF-1 activation induces doxorubicin resistance in MCF7 3-D spheroids via P-glycoprotein expression: a potential model of the chemo-resistance of invasive micropapillary carcinoma of the breast BMC Cancer 2012 12 1 22212211
39 Chen J Ding Z Peng Y Pan F Li J Zou L Zhang Y Liang H inhibition reverses multidrug resistance in colon cancer cells via downregulation of MDR1/P-glycoprotein PloS One 2014 9 e98882 24901645
40 Liao XM Tang WX Lai JJ Pu SP Sun SL Effect of Calcium Signal on Expression of HIF-lα in Breast Cancer Cell Line and Invasion and Metastasis of Cells J Fourth Mil Med Univ 2009 1 49 52
41 Liu DL Li YJ Yang DH Wang CR Xu J Yao N Zhang XQ Chen ZS Ye WC Zhang DM Ganoderma lucidum derived ganoderenic acid B reverses ABCB1-mediated multidrug resistance in HepG2/ADM cells Int J Oncol 2015 46 2029 2038 25779097
42 Ghafoory S Mehrabi A Hafezi M Cheng X Breitkopf-Heinlein K Hick M Huichalaf M Herbel V Saffari A Wölfl S Nuclear accumulation of CDH1 mRNA in hepatocellular carcinoma cells Oncogenesis 2015 4 e152 26029826
43 Li A Song J Lai Q Liu B Wang H Xu Y Feng X Sun X Du Z Hypermethylation of ATP-binding cassette B1 (ABCB1) multidrug resistance 1 (MDR1) is associated with cisplatin resistance in the A549 lung adenocarcinoma cell line Int J Exp Pathol 2016
44 Zhang W Lei XJ Wang YF Wang DQ Yuan ZY Role of Kir2.1 in human monocyte-derived foam cell maturation J Cell Mol Med 2016 20 403 412 26689595
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
오픈액세스 학술지에 출판된 논문
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.